This study was supported by grants from the National Key Technology R&D Program (Nos. 2013BAI09B05 and 2015BAI12B06), Key Program of the National Natural Science Foundation of China (No. 81330019), General Program of the National Natural Science Foundation of China (No. 81270794), and the Beijing Science and Technology Project (No. D 131100004713003 and No. D171100002817002).
Background: Chronic kidney disease (CKD) with moderate-to-severe renal dysfunction usually exhibits an irreversible course, and available treatments for delaying the progression to end-stage renal disease are limit...
Supported by the Eleventh Five-Year National Key Technology R&D Program(No.2007BAI20B092)
To assess the efficacy and safety of Gastrosis No.1 compound in the treatment of functional dyspepsia with Spleen (Pi) and Stomach (Wei) deficiency-cold syndrome. Methods: A randomized, double-blind, placebo-cont...
Supported by Chinese State Key Project for High Technology, No. 2006AA02A308;National Key Technology R&D Program, No. 2008BAI52B03;Science and Technology Foundation of Zhejiang Province, No. 2008C13027-1
AIM: To investigate the early mortality of placebo-treated alcoholic hepatitis patients. METHODS: Mortality data about alcoholic hepatitis patients who participated in randomized placebo-controlled trials were searche...